Abstract:Background: The role of RASGRF2 has been verified in the development of various cancers. However, its roles in stomach adenocarcinoma (STAD) are still under investigation. Methods: RASGRF2 transcript-level data and the associated clinical information from patients with STAD were extracted from The Cancer Genome Atlas (TCGA). Diagnostic and prognostic values of RASGRF2 were analyzed using receiver-operator characteristics (ROC) analysis, correlation analysis, and survival analysis in conjunction with a prognostic model. In addition, gene expression profiles, differentially-expressed genes for co-varying expression, and a differential expressed genes (DEG) protein-protein interaction network for influential nodes were also analyzed. To identify the molecular role of RASGRF2 in STAD, gene ontology (GO) term, Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway, and gene set enrichment analysis (GSEA)-mediated functional module enrichment analyses were conducted. The relationship between RASGRF2 and gene signature-based predicted immune cell infiltration patterns were also investigated. To validate the bioinformatic findings, RASGRF2 protein expression was investigated in vitro using western blot and immunohistochemistry. Furthermore, relationships among RASGRF2 protein expression, clinicopathologic characteristics, and patient survival were analyzed. Results: Bioinformatic analysis revealed a significantly higher RASGRF2 transcript level in STAD tissue, which was positively associated with the T stage, histological type, histological grade, and TP53 status. Moreover, the RASGRF2 transcript level indicated poor overall survival in STAD patients (hazard ratio = 1.47, P = 0.023). Multivariate Cox regression analysis showed that primary therapy outcome, age, and RASGRF2 transcript level were independent prognostic factors for survival, and the C-index of a nomogram was 0.695. Additionally, 159 genes were differentially expressed according to RASGRF2 transcript levels; 15 exhibited co-varying expression, and 13 were identified as influential nodes. The DEG-list was significantly enriched for several GO terms, biological pathways, and functional modules, including MAPK, RAS, ERK, and immunoregulatory pathways. RASGRF2 transcript levels were significantly positively correlated with infiltration levels of Tem, Macrophages, pDCs, and NK cells. Validation analysis showed similar results for the RASGRF2 protein expression level in both in vitro analyses. Conclusion: Bioinformatic predictions combined with in vitro validation suggest that RASGRF2 plays diagnostic and prognostic roles and serves as a negative protective molecular factor in STAD patients.

Anterior Gradient Protein 2 Expression in High Grade Head and Neck Squamous Cell Carcinoma Correlated with Cancer Stem Cell and Epithelial Mesenchymal Transition

AGR2 Promotes the Proliferation, Migration and Regulates Epithelial-Mesenchymal Transition in Salivary Adenoid Cystic Carcinoma

AGR2 is associated with gastric cancer progression and poor survival.

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.

AGR2: A Potential Diagnostic Biomarker for Cervical Cancer

Prevalence and Significance of AGR2 Expression in Human Cancer

AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma

FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma

CSRP2 Influences cell Stemness and Prognosis in Head and Neck Cancer

ECT2 promotes the occurrence and is a prognostic biomarker of head and neck squamous cell carcinoma

AGR2 – a Novel Predictor of Neoadjuvant Chemoradiotherapy Response in Esophageal Squamous Cell Carcinoma

High Expression of ERK-related RASGRF2 Predicts Poor Prognosis in Patients with Stomach Adenocarcinoma and Correlates with M2 Macrophage

Research Advance of Pro-Metastatic Protein Anterior Gradient-2

Title SETDB 1 accelerates tumourigenesis by regulating the WNT signalling pathway

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

CSRP2 promotes cell stemness in head and neck squamous cell carcinoma

High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma.

The Involvement of Anterior Gradient 2 in the Stromal Cell-Derived Factor 1-Induced Epithelial-Mesenchymal Transition of Glioblastoma

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer

Intracellular AGR2 transduces PGE2 stimuli to promote epithelial–mesenchymal transition and metastasis of colorectal cancer

Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response